Sun Pharmaceuticals Industries has received approval from the Drugs Controller General of India (DCGI) to initiate a clinical trial with Nafamostat Mesilate in Covid-19 patients. Nafamostat is approved in Japan for improvement of acute symptoms of pancreatitis and treatment of Disseminated Intravascular Coagulation (DIC).
Sun Pharma Industries Limited receeives clinical trial approval for which drug to treat COVID-19 patients?
Where am I?
In Safejob Community you can ask and answer questions and share your experience with others!
"Sun Pharma is constantly evaluating potential targets that can be explored for treating Covid-19 patients," said Managing Director Dilip Shanghvi.
"Nafamostat has shown promising data against SARS-CoV-2 virus in in vitro studies conducted by three independent groups of scientists in Europe, Japan and South Korea. We believe it holds promise in the treatment of Covid-19 patients," he said in a statement.
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Delivering products for customers and patients in over 100 countries, its global presence is supported by manufacturing facilities spread across six continents which are approved by multiple regulatory agencies.